Temsirolimus Plus Bortezomib Safe, Active for Relapsed/Refractory B-Cell NHL
the ONA take:
The combination of a mammalian target of rapamycin inhibitor and a proteasome inhibitor is safe and has activity in heavily pretreated patients with B-cell non-Hodgkin lymphoma, a recent study published in the journal Cancer has shown.
For the single-arm, phase 2 trial, researchers enrolled 39 patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
The patients received bortezomib and temsirolimus weekly on days 1, 8, 15, and 22 of a 35-day cycle. This dosing scheme has previously been studied in patients with multiple myeloma.
Results showed that 7.7% of patients achieved a complete response and 23% achieved a partial response. Median progression-free survival was 4.7 months (2 months for patients with diffuse large B-cell lymphoma, 7.5 months for those with mantle cell lymphoma, and 16.5 months for those with follicular lymphoma).
Researchers found that two extensively treated patients with diffuse large B-cell lymphoma achieved a complete response. In regard to safety, there were no unexpected toxicities with the combination.
“Further studies with this combination are warranted in specific subtypes of NHL,” the authors conclude.
The combination of a mammalian target of rapamycin inhibitor and a proteasome inhibitor is safe in B-cell non-Hodgkin lymphoma.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|